Philips Lifeline, Inc. – FDA Warning Letter, Dec 4, 2007

The FDA issued a Warning Letter to Philips Lifeline, Inc.'s subsidiary, Health Watch, Inc., following a December 3-4, 2007 inspection. The inspection revealed that the firm's 3000 and 6000 model Health Watch Personal Response System, a Class II medical device, is adulterated under section 501(h) of the Act. This is due to non-conformity with the Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) regulation (21 C.F.R. Part 820).

Key violations include the failure to implement an adequate and effective quality system with management oversight (21 C.F.R. § 820.20), specifically lacking procedures for Corrective and Preventive Actions (CAPA) (21 C.F.R. § 820.100(a)), environmental controls (21 C.F.R. § 820.70(c)), document control (21 C.F.R. § 820.40), and complaint handling (21 C.F.R. § 820.198(a)). Additionally, the firm failed to document calibration dates for equipment (21 C.F.R. § 820.72(b)(2)) and establish adequate training procedures for personnel (21 C.F.R. § 820.25(b)).

The FDA deemed the firm's response inadequate, rejecting its claim of no longer being a device manufacturer, as activities like battery replacement and functional checks constitute manufacturing. The firm must promptly correct all violations, provide a written response within 15 working days detailing corrective actions, prevention plans, and timelines. Failure to comply could result in regulatory actions, including seizure, injunction, civil penalties, and impact on federal contracts and device approvals. The firm also needs to address the maintenance of its [redacted] installed systems.